KTOV News and Press, Kitov Pharma Ltd. From 10/23/20

Socket Mobile (SCKT) +123% on Q3 results.Dogness (DOGZ) +60% after announcing partnership with Hangzhou Huayuan Pet Products and Shanghai Chongai Trading Co. Ltd.Zedge (ZDGE) +47% on Q4 results.Solid Biosciences (SLDB) +28% on announcing collaborat...

Kitov Pharma (KTOV) has announced new mechanism of action data of NT219, a dual inhibitor, small molecule targeting IRS1/2 and STAT3. Data were presented at the Epigenetics and Metabolism AACR Special Virtual Conference at Tel-Aviv University.The new data demonstrates IRS2-amplified colorecta...

Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance TEL AVIV, Israel, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion ...

Kitov Pharma (NASDAQ: KTOV ) announces that the first patient has been dosed in the Phase 1/2 clinical trial evaluating NT219 as monotherapy treatment of advanced solid tumors, as well as in combination with cetuximab, for the treatment of recurrent and/or metastatic solid tumors and hea...

TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the first patient has been dosed in th...

Kitov Pharma (NASDAQ: KTOV ) announces receipt of notification from the Chinese Patent Office to grant two separate patents for its lead oncology candidates CM24, a monoclonal antibody targeting CEACAM1, and NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3, import...

Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries TEL AVIV, Israel, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class t...

Gevo (NASDAQ: GEVO )   -26%  on launch of direct offering ; pared down overnight gains after Trafigura deal . More news on: Gevo, Inc., GAN Limited, Xcel Brands, Inc., Stocks on the move, , Read more ...

Kitov Pharma (NASDAQ: KTOV ) has changed the ratio of its ADSs to ordinary shares from 1 ADS representing 1 ordinary shares to a new ratio of 1 ADS representing 10 ordinary shares . More news on: Kitov Pharma Ltd, Read more ...

TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced today that the Company will change the ratio of its ...